Phathom Pharmaceuticals Stock In The News
| PHAT Stock | USD 6.42 0.03 0.47% |
Our overall analysis of Phathom Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Phathom Pharmaceuticals. The specific impact of Phathom Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Phathom Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Phathom Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Phathom Pharmaceuticals Backtesting and Phathom Pharmaceuticals Hype Analysis. For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.
Phathom |
Phathom Pharmaceuticals Today Top News and Investor Outlook
Phathom Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Phathom and other traded companies coverage with news coverage. We help investors stay connected with Phathom headlines for the 26th of March to make an informed investment decision based on correlating the impacts of news items on Phathom Stock performance. Please note that trading solely based on the Phathom Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Phathom Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Phathom earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Phathom Pharmaceuticals that are available to investors today. That information is available publicly through Phathom media outlets and privately through word of mouth or via Phathom internal channels. However, regardless of the origin, that massive amount of Phathom data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Phathom Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Phathom Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Phathom Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Phathom Pharmaceuticals alpha.
Phathom Largest EPS Surprises
Earnings surprises can significantly impact Phathom Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-08-06 | 2020-06-30 | -0.56 | -0.64 | -0.08 | 14 | ||
2022-05-10 | 2022-03-31 | -0.97 | -1.07 | -0.1 | 10 | ||
2020-05-12 | 2020-03-31 | -0.72 | -0.62 | 0.1 | 13 | ||
2023-11-09 | 2023-09-30 | -0.89 | -0.76 | 0.13 | 14 | ||
2023-08-10 | 2023-06-30 | -0.98 | -0.84 | 0.14 | 14 | ||
2024-11-07 | 2024-09-30 | -1.49 | -1.32 | 0.17 | 11 |
Phathom Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Phathom Pharmaceuticals Stock. Current markets are slightly bullish. About 51% of major world exchanges and indexes are currently up. See today's market update for more information.
19th of March 2025
Phathom Pharmaceuticals price target lowered to 13 from 17 at Jefferies - TipRanks at news.google.com
13th of March 2025
Acquisition by Parikh Asit of 10000 shares of Phathom Pharmaceuticals at 4.42 subject to R... at Parikh Asit
12th of March 2025
Disposition of 2032 shares by Henderson Molly of Phathom Pharmaceuticals at 8.5309 subject... at MacroaxisInsider
7th of March 2025
Q4 2024 Phathom Pharmaceuticals Inc Earnings Call Transcript at gurufocus.com
6th of March 2025
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and ..... at gurufocus.com
5th of March 2025
Disposition of 6307 shares by Henderson Molly of Phathom Pharmaceuticals at 7.7533 subject... at finance.yahoo.com
28th of February 2025
Cantor Fitzgerald Upgrades Phathom Pharmaceuticals to Strong-Buy - MarketBeat at news.google.com
24th of February 2025
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and ... at globenewswire.com
6th of February 2025
Disposition of 1960 shares by Henderson Molly of Phathom Pharmaceuticals at 11.4121 subjec... at Henderson Molly
21st of January 2025
Disposition of 19109 shares by Terrie Curran of Phathom Pharmaceuticals at 6.5877 subject ... at Terrie Curran
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Phathom Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Phathom Pharmaceuticals' short interest history, or implied volatility extrapolated from Phathom Pharmaceuticals options trading.
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.